1-4 of 4
Karin Knobe
Close
Sort by
Journal Articles

Phase 1 Repeat Dosing with BIVV001: The First Investigational Factor VIII Product to Break through the Von Willebrand Factor-Imposed Half-Life Ceiling

Toshko Lissitchkov, Kara Rice, Suresh Katragadda, Annemieke Willemze, Craig Benson, Karin Knobe
Journal: Blood
Blood (2019) 134 (Supplement_1): 625.
https://doi.org/10.1182/blood-2019-122211
Published: 2019
Journal Articles

Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial

Clinical Trials & Observations
Peter W. Collins, Guy Young, Karin Knobe, Faraizah Abdul Karim, Pantep Angchaisuksiri, Claus Banner, Türkiz Gürsel, Johnny Mahlangu, Tadashi Matsushita, Eveline P. Mauser-Bunschoten, Johannes Oldenburg, Christopher E. Walsh, Claude Negrier
Journal: Blood
Blood (2014) 124 (26): 3880–3886.
https://doi.org/10.1182/blood-2014-05-573055
Published: 2014
Includes: Supplemental data
Journal Articles

Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B

Clinical Trials & Observations
Claude Negrier, Karin Knobe, Andreas Tiede, Paul Giangrande, Judi Møss
Journal: Blood
Blood (2011) 118 (10): 2695–2701.
https://doi.org/10.1182/blood-2011-02-335596
Published: 2011
Journal Articles

Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide

Henrik Østergaard, Jais R. Bjelke, Lene Hansen, Lars Christian Petersen, Anette A. Pedersen, Torben Elm, Flemming Møller, Mette B. Hermit, Pernille K. Holm, Thomas N. Krogh, Jørn M. Petersen, Mirella Ezban, Brit B. Sørensen, Mette D. Andersen, Henrik Agersø, Haleh Ahmadian, Kristoffer W. Balling, Marie Louise S. Christiansen, Karin Knobe, Timothy C. Nichols, Søren E. Bjørn, Mikael Tranholm
Journal: Blood
Blood (2011) 118 (8): 2333–2341.
https://doi.org/10.1182/blood-2011-02-336172
Published: 2011
Includes: Supplemental data